Clinical Trial Update: The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder. [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the efficacy, safety, and tolerability of CP-866,087 in pre-menopausal women with female sexual arousal disorder; the study has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Female Sexual Arousal Disorder

Drugs mentioned

• CP-866,087

Snippet

Sponsor: Pfizer | Conditions: Sexual Dysfunction, Physiological | Phase 2 | Status: COMPLETED